PEGS Summit Korea
PEGS Korea

TRACK 1

Protein & Antibody Engineering

September 20-21

The field of biotherapeutics is experiencing an unparalleled level of interest, thanks to the clinical and regulatory successes of antibody-drug conjugates, bispecifics and immuno-modulating antibodies. As more and more of these novel molecules enter the clinic, the industry is rife with new targets, new technologies, new chemistries and new formats that are pushing the envelope in novel therapeutic engineering and design.

The Protein & Antibody Engineering track aims to explore antibodies and vaccines for emerging infectious diseases such as MERS-CoV, SARS and Hepatitis-B; highlight antibody discovery and engineering techniques including high throughput platforms; showcase emerging target discovery and validation; and share examples in antibody-drug conjugates design and engineering.  

Continue your exploration by attending the accompanying event – Cancer Immunotherapy – to hear all about the current development, strategies and clinical updates on immune checkpoint inhibitors, adoptive T cell therapies and combination immunotherapies.

Final Agenda

Download Brochure | Speaker Bios

TUESDAY, SEPTEMBER 20, 2016

7:30 am Registration and Morning Coffee

8:30 Chairperson’s Opening Remarks

Junho Chung, Ph.D., Professor, Biochemistry and Molecular Biology, Seoul National University


KEYNOTE PRESENTATIONS

William Strohl8:40 Protease-Resistant Antibodies for Use as Anti-Cancer Agents and Methicillin-Resistant Staphylococcus aureus (MRSA)

William R. Strohl, Ph.D., Consultant, (former Vice President and Fellow, Janssen Biotherapeutics, Janssen Research & Development, LLC.)

Engineered antibodies with fit-for-purpose properties will differentiate next generation antibody therapeutics from traditional IgG1-based therapeutics. We have demonstrated that proteases secreted by invasive tumors and pathogens site-specifically cleave human IgG1, rendering it functionally inactive, as a potential mechanism for evading host immune response. We have engineered protease-resistant antibodies with potent cellkilling functions for use as anti-Staphylococcus aureus agents.

Dimiter Dimitrov9:20 Antibody-Based Candidate Therapeutics against Emerging Viruses and HIV-1

Dimiter Dimitrov, Ph.D., Senior Investigator, Cancer Inflammation Program, National Cancer Institute, NIH

We identified and characterized a number of highly potent human antibodies and engineered antibody domains (eAds) against SARS- and MERS-CoVs (m336), Hendra and Nipah viruses (m102.4), and Dengue, as well as against HIV-1. m102.4 was administered to humans. m336 was successful in three animal models and showed great promise for further development. The eAd-based proteins against HIV-1 were successful in animal models and are being further developed for its eradication.


ANTIBODIES AND VACCINES AGAINST INFECTIOUS DISEASES

10:00 Coffee Break

10:30 MERS-CoV: Opportunity for Drug Discovery in Korea

Ji-Young_MinJi-Young Min, Ph.D., Principal Investigator, Head, Respiratory Viruses Research Laboratory, Discovery Biology Department, Institut Pasteur Korea

Screening for and optimization of small molecule hits can provide a powerful compound by which the latent biology can be dissected to further our understanding of the biological processes. Presented in this talk are innovative phenomic approaches that are not only helping to shed a new light on the discovery of first-in-class compound with novel molecular mechanism of MERS-CoV infection, but also providing a great hope of fighting some of the more devastating outbreaks in new ways.

11:00 Celltrion’s Antibody Pipeline for the Treatment of Infectious Diseases

Kye_Sook_YiKye Sook Yi, Ph.D., Senior Manager and Team Leader, New Antibody Development, R&D, Celltrion

Ebola virus disease and MERS are well-known infections where treatment has included convalescent plasma therapies for some patients. However, serum, and even purified polyclonal antibodies from serum, have several disadvantages. These include limitations in supply, safety concerns due to immunogenicity and viral contamination, and low specific titers. Here, we introduce our pipeline of new antibodies, developed using a platform technology, which target infectious diseases such as influenza A, Rabies and Hepatitis B virus.

11:30 Fc Engineering and Antibody Development against Infectious Diseases

Tianlei_YingTianlei Ying, Ph.D., Professor, Antibody Engineering and Drug Discovery Group, Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, China

Therapeutic modalities based on monoclonal antibodies (mAbs) have shown clinical success in the treatment of many diseases. By using extraordinarily large human antibody libraries and in vitro display technologies, we have identified potent neutralizing mAbs against emerging infectious diseases and cancer. We are also applying antibody engineering techniques to rapidly develop cheaper, safer and more potent antibody-based therapeutics.

12:00 pm Shortening the Biotherapeutic Development Timeline: Multi-Gram Yield Antibody Production via Scalable Electroporation

Peer Heine, Ph.D., Field Application Scientist, Research & Development, MaxCyte

Data developed with MaxCyte’s flow electroporation will demonstrate the production of multiple grams of antibodies, bispecifics, and non-antibody like recombinant proteins following a single transient transfection. Its scalability with CHO, HEK293, insect cells, and other commonly used cells in bioproduction will be demonstrated as well as the rapid generation of high-yield stable cell lines(titer of 6 g/L) within 6-8 weeks of transfection. The glycosylation of stable vs. transiently produced protein will be examined

12:30 Networking Luncheon in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

1:55 Chairperson’s Remarks

Dimiter Dimitrov, Ph.D., Senior Investigator, Cancer Inflammation Program, National Cancer Institute, NIH

2:00 Development of Nanoantibodies against Viral Infection and Cancer

Rui_GongRui Gong, Ph.D., Professor & Head, Antibody Engineering Group, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences

Antibody constant CH2 domain is a promising scaffold for development of nanoantibodies that can not only bind to specific antigens but also offer certain Fc effector functions. Here, we report that new candidate clones against viral and tumor antigens were identified based on modified CH2 domain with increased stability and aggregation resistance. We show that the nanoantibody technology could be a useful platform for selection of nanoantibodies against various antigens with potential for further clinic use.

2:30 Epitope-Based Vaccines: Reconstitution of Conformational Discontinuous Epitopes

Jonathan_GershoniJonathan M. Gershoni, Ph.D., Professor, Cell Research and Immunology, Tel Aviv University

Prophylactic vaccines elicit the production of antibodies intended to neutralize invading pathogens. The ability to focus this immune response towards neutralizing epitopes is a major challenge. We describe a method for the production of epitope-based immunogens where conformational discontinuous epitopes are functionally reconstituted. As a case in point we have reconstituted the receptor binding motif (RBM) of SARS Coronavirus and discuss this in the context of combating emerging Coronaviral diseases.

3:00 Anti-MERS Virus Antibody and Anti-SFTS Virus Antibody

Junho Chung, Ph.D., Professor, Biochemistry and Molecular Biology, Seoul National University

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing


ANTIBODY-DRUG CONJUGATES DESIGN AND DEVELOPMENT

4:15 Sweet Delivery of the Bitter – Using Carbohydrate-Targeting Antibodies for Tumor-Specific Delivery of Cytotoxic Drugs

Felix Hart, Scientist, Preclinical Pharmacology & ADCs, Glycotope GmbH

Antibody-drug conjugates have great potential to specifically deliver cytotoxic agents to cancer cells. Carbohydrates on the surface of cancer cells represent promising targets for the specific delivery of cytotoxic drugs for cancer therapy. Tumor specificity and Fc-mediated effector functions were shown by immunohistochemistry and antibody-dependent cellular cytotoxicity, respectively. As prerequisites for intracellular drug delivery, target internalization upon antibody binding and lysosomal localization was confirmed. Moreover, surrogate ADCs using different cytotoxic agents inhibited proliferation of antigen-positive cancer cell lines.

4:45 Site-Specific Conjugation: Improving Homogeneity and Other Druggability Properties for Antibody-Drug Conjugates

Bruce_Nianhe_HanBruce Nianhe Han, Ph.D., CSO, NewBio Therapeutics

We have discovered new linkers, bis(maleimde)derivatives which can conjugate small molecule toxins to antibodies in site-specific manner. One of the advantages of this technology is that we don’t need to do any antibody engineering and just use the interchain disulfide bonds of IgG to perform conjugation. The resulting final products have a high percentage of ADC with defined antibody-drug ratios. Also, these more homogeneous ADCs have shown improved in vitro and in vivo stability, and other related druggability properties.

5:15 Shortening Preclinical Development of Stable and Efficacious Site Specific ADCs: Use of Engineered Transglutaminase on Un-Modified Antibodies

Sean_HuSean Hu, Ph.D., Founder, Dophen Biomed

Site-specific ADCs are made in a one-pot reaction directly from un-modified mAbs using engineered transglutaminase. Such ADCs are 4 to 8 times more efficacious in xenograft models than their counterparts of random conjugation via lysine residues and display wider therapeutic windows in GLP toxicology study. This platform uses your mAbs off the shelves and the reaction yields are as high as 98%, leaving no naked antibody to be removed. Thus, the manufacturing process is significantly simplified.

5:45 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 Close of Day

 Download Brochure

WEDNESDAY, SEPTEMBER 21, 2016

7:45 am Registration and Morning Coffee

8:30 Chairperson’s Remarks

Yong-Sung Kim, Ph.D., Professor, Molecular Science & Technology, Ajou University


ANTIBODY DISCOVERY AND ENGINEERING

8:40 An Innovative High-Throughput Platform for Next-Generation Discovery of Multipurpose Binders

Jonas_SchaeferJonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Department of Biochemistry, University of Zurich

To optimize the efficiency and capacity of the laborious process of generating specific affinity reagents, we established a streamlined pipeline consisting of simultaneous selections against 94 targets and subsequent high-throughput screenings and validations. This fast and efficient platform allows the reliable discovery of recombinant binders to improve existing and to enable the development of novel innovative applications (from basic research to improved diagnostics) like elucidating intracellular pathways, amongst others.

9:10 Antibody Libraries Based on an Autonomous Human Variable Domain

Johan_NilvebrantJohan Nilvebrant, Ph.D., Researcher, Protein Technology, Royal Institute of Technology

We have constructed two synthetic libraries based on an engineered autonomous human variable heavy (VH) domain. We integrated a CDR design aimed to alleviate aggregation problems that are commonly associated with domain antibodies. Binders to all human Eph receptors, many of which are implicated in cancer, have been selected. The domain antibodies typically compete with ligand for binding and represent promising candidates to engineer novel receptor agonists and antagonists.

9:40 Stable Human Antibody Therapeutics through Variable Domain Engineering

Daniel_ChristDaniel Christ, Ph.D., Associate Professor and Director, Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research

Human antibody reagents often display poor biophysical properties and a propensity to aggregate. We have identified aggregation hotspots in the CDR regions of antibody variable domains, and have developed generally applicable strategies to overcome these limitations. Here we present recent advances in the application of the technology to antibody fragments, as well as to the stabilization of the FDA approved therapeutics and clinical candidates.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing


TARGET DISCOVERY AND VALIDATION

10:50 Antibodies Targeting Peptide/HLA Complexes forCancer Therapy

Julia_NeugebauerJulia Neugebauer, Ph.D., Assistant Director, Discovery, Alliances & Technologies, Morphosys AG

Tumor-specific peptide/HLA complexes make intracellular targets accessible to antibodies. However, the generation of therapeutic antibodies, which recognize a particular peptide/HLA complex specifically, is highly challenging. By identifying and applying appropriate counter-targets, we generated fully human, high affinity antibodies against a WT1 peptide/HLA complex. These antibodies bind to target-positive cancer cell lines and outperform similar state-of-the-art antibodies regarding target specificity and binding affinity.

11:20 Targeting Intracellular Oncogenic Proteins by Cytosol-Penetrating Antibody

Yong-Sung_KimYong-Sung Kim, Ph.D., Professor, Molecular Science & Technology, Ajou University

The ability of an IgG-format antibody to reach the cytosol of target mammalian cells from outside of cells is highly desired for diverse purposes of research, diagnostic and therapeutic applications. In this talk, we will introduce a new antibody technology, in which human IgG-format antibody can access the cytosol of living cells after internalization and specifically bind to cytosolic oncogenic proteins, thereby showing anti-tumor efficacy.

11:50 Clec14a as a Novel Therapeutic Target in Angiogenesis: A New Challenge with Antibody-Based Targeting of VEGF

Sukmook_LeeSukmook Lee, Ph.D., Principal Investigator, Research Center, Scripps Korea Antibody Institute

Clec14a is a type I transmembrane protein that is exclusively expressed on endothelial cells. In this talk, I will first highlight the relevance and role of clec14a in angiogenesis. With a human monoclonal antibody we have developed, I will also provide the proof-of-concept that antibody-based targeting of clec14a may be effective and the antibody has therapeutic potential for suppressing pathological angiogenesis for antibody therapy.

12:20 pm Sponsored Presentation (Opportunity Available)

12:50 Networking Luncheon in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)




Download Brochure | Speaker Bios


Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Register Now

Arrow Right ColDownload 2016 Brochure

2016 PEGS Korea Brochure

 

Arrow Right ColCorporate Sponsor

 MaxCyte

Arrow Right ColCorporate Support Sponsors


GeneScript

Nicoya

 

 Thermo Fisher Scientific


Arrow Right ColSponsoring Organizations


AntibodySocietyLogo
 
Antibody Society Korea



Arrow Right ColView All Media Partners


 

Track 1
Protein & Antibody Engineering


Track 2
Cancer Immunotherapy